SOUTH SAN FRANCISCO, CA--(Marketwire - January 17, 2008) - Theravance, Inc. (NASDAQ: THRX), a biopharmaceutical company with a pipeline of internally discovered product candidates, today announced that it has entered into an agreement to sell $150.0 million aggregate principal amount of unsecured 3% convertible subordinated notes due 2015 in an underwritten registered public offering. In addition, Theravance has granted the underwriters a 30-day option to purchase on the same terms and conditions up to an additional $22.5 million aggregate principal amount of notes to cover over-allotments. The Company intends to use the net proceeds from the offering for general corporate purposes.
